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Anti-Inflammatory and Cardioprotective Effects of
Tadalafil in Diabetic Mice
Amit Varma, Anindita Das, Nicholas N. Hoke, David E. Durrant, Fadi N. Salloum, Rakesh C. Kukreja*
Division of Cardiology, Department of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, United States of America

Abstract
Background: Insulin resistance impairs nitric oxide (NO) bioavailability and obesity promotes a state of chronic
inflammation and damages the vascular endothelium. Phosphodiesterase-5 inhibitors restore NO signaling and may reduce
circulating inflammatory markers, and improve metabolic parameters through a number of mechanisms. We hypothesized
that daily administration of the PDE-5 inhibitor, tadalafil (TAD) will attenuate inflammation, improve fasting plasma glucose
and triglyceride levels, body weight, and reduce infarct size after ischemia/reperfusion injury in obese, diabetic mice.
Methods: Twenty leptin receptor null (db/db) mice underwent treatment with TAD (1 mg/Kg) or 10% DMSO for 28 days.
Body weight and fasting plasma glucose levels were determined weekly. Upon completion, hearts were isolated and
subjected to 30 min global ischemia followed by 60 min reperfusion in a Langendorff model. Plasma samples were taken
for cytokine analysis and fasting triglyceride levels. Infarct size was measured using computer morphometry of tetrazolium
stained sections. Additionally, ventricular cardiomyocytes were isolated and subjected to 40 min of simulated ischemia and
reoxygenation. Necrosis was determined using trypan blue exclusion and LDH release assay and apoptosis was assessed by
TUNEL assay after 1 h or 18 h of reoxygenation, respectively.
Results: Treatment with TAD caused a reduction in infarct size in the diabetic heart (23.261.5 vs. 47.863.7%, p,0.01, n = 6/
group), reduced fasting glucose levels (292631.8 vs. 511619.3 mg/dL, p,0.001) and fasting triglycerides (43.3621 vs.
129.7629 mg/dL, p,0.05) as compared to DMSO, however body weight was not significantly reduced. Circulating tumor
necrosis factor-a and interleukin-1b were reduced after treatment compared to control (257616.51 vs. 402.3617.26 and
150.8612.55 vs. 264631.85 pg/mL, respectively; P,0.001) Isolated cardiomyocytes from TAD-treated mice showed
reduced apoptosis and necrosis.
Conclusion: We have provided the first evidence that TAD therapy ameliorates circulating inflammatory cytokines and
chemokines in a diabetic animal model while improving fasting glucose levels and reducing infarct size following ischemiareperfusion injury in the heart.
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(NO) within the vascular endothelium contributes to impaired
insulin utilization in patients with insulin resistance [2]. Vascular
NO is critical for normal vasodilatation and endothelial function,
and impairment of NO bioavailability and the NO-cyclic
guanosine monophosphate (cGMP)-cGMP-dependent protein
kinases (PKG) signaling cascade can lead to endothelial dysfunction [3]. A number of clinical studies have shown that
hyperglycemia and increased AGEs are key factors in potentiating
vascular inflammation and increasing levels of reactive oxygen
species (ROS) and oxidative stress [4,5]. This vascular milieu of
elevated inflammation, impaired NO bioavailability, and oxidative
stress plays an integral role in the progression of atherosclerosis
and subsequently acute coronary syndromes culminating in
significant morbidity and mortality of the diabetic patient [6].
Recent animal studies with NO synthase (NOS) inhibitors and
endothelial NOS (eNOS) gene, suggest that the NO signaling

Introduction
The prevalence of diabetes in the United States in increasing at
an astronomical rate and the American Diabetes Association
currently estimates that 8.3% of the population has diabetes and
nearly 79 million people have insulin resistance and are at risk for
developing diabetes [1]. Insulin resistance and diabetes lead to a
number of micro- and macro- vascular insults leading to
retinopathy, nephropathy and painful neuropathy and eventually
more adverse complications such as atherosclerosis, coronary
artery disease, and cerebrovascular disease. The increased
incidence of these complications has been attributed to higher
levels of inflammatory cytokines, chronic hyperglycemia leading to
formation of advanced glycation end products (AGEs) and
elevated levels of oxidative stress leading to endothelial dysfunction. There is data to suggest that reduced levels of nitric oxide
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pathway may regulate and promote glucose uptake in myocytes
[7–10]. Moreover, eNOS knockout mice had decreased oxygen
consumption, increased weight gain and were resistant to insulin
[11]. In addition, several studies have indicated that insulin
resistance itself may impair NO release and damage the
endothelium through mechanisms that are reciprocally interconnected [4,5]. For example, chronic hyperglycemia has been shown
to increase circulating levels of inflammatory cytokines, chemokines, and expression of intracellular adhesion molecule-1, hence
contributing further to this pathognomonic state [12].
The PDE-5 inhibitors, including sildenafil (ViagraTM), vardenafil (LevitraTM), tadalafil (CialisTM) and avanafil (Stendra) have
been approved by the Food and Drug Administration for the
treatment of erectile dysfunction (ED). Sildenafil and tadalafil
(TAD) have also been approved for the management of
pulmonary arterial hypertension [13]. A number of preclinical
studies from our laboratory have shown that PDE-5 inhibitors
have a powerful protective effect against myocardial ischemia/
reperfusion (I/R) injury [14–18], doxorubicin and post-MI heart
failure [19–23]. Mechanistically, we showed that sildenafil protects
the heart against I/R injury through increased expression of
inducible NOS (iNOS)/eNOS [24,25], activation of cGMPdependent protein kinase, PKG [25,26], phosphorylation of
glycogen synthase kinase-b (GSK-3b) [26], opening of mitochondrial KATP channels [14–16], and hydrogen sulfide generation
[27]. Chronic administration of PDE-5 inhibitors has been
associated with increased persistent vascular and endothelial
function by increasing the level of endothelial cGMP generated
by activation of eNOS [24,27]. In streptozotocin-induced diabetic
rats, long-term administration of the PDE-5 inhibitor, DA-8159,
prevented ED and preserved endothelial function [28]. In a similar
model, 14 days of treatment with sildenafil improved vasorelaxation through enhanced endogenous NO signaling [29]. In
addition, clinical studies have revealed a potential protective role
of these compounds on endothelial function in short- and longterm assessments [30]. In a large meta-analysis, it was reported
that endothelial dysfunction is a significant independent risk factor
for cardiac death, myocardial infarction (MI), stroke and the need
for coronary revascularization [31]. Diabetic patients with ED
were at increased risk for silent coronary artery disease and ED
was a powerful predictor of cardiovascular (CV) morbidity and
mortality [32]. A recent epidemiological study provided evidence
of a strong correlation between the risk factors associated with
metabolic syndrome (i.e. obesity, elevated fasting glucose levels,
dyslipidemia, hypertension) and urinary cGMP excretion, suggesting that a reduction of NO bioactivity concurs with these CV
risk factors [33]. Moreover, genetic variations of eNOS gene
influenced energy expenditure, severity of glucose intolerance and
risk of developing type II diabetes [34]. Chronic (alternate-day)
administration of TAD in men with ED had improved endothelial
function as indicated by marked changes in serum markers of
endothelial function, increased insulin levels and a robust decrease
in the inflammatory marker, high sensitivity C-reactive protein (hsCRP) [35]. Furthermore, both acute and chronic administration of
sildenafil improved endothelial function in patients with type-2
diabetes as observed by improved flow-mediated dilatation of the
brachial artery [36,37].
The diabetic myocardium is especially vulnerable to I/R injury
and studies on obese diabetic animals models with hyperinsulinemia have confirmed this finding [38,39]. Although the underlying
mechanisms remain to be fully elucidated, a number of hypotheses
have been proposed. Diabetics and models of hyperglycemia
exhibit significantly higher levels of ROS production which impair
mitochondrial energy metabolism and readily lead to cardiomyPLOS ONE | www.plosone.org

ocyte apoptosis [40]. Likewise, the diabetic heart preferentially
uses free fatty acids as an energy source and this requires nearly
12% more oxygen per adenosine triphosphate generated than
when glucose is utilized [41]. Similarly, during ischemia, the
diabetic myocardium does not have the ability to switch to glucose
utilization for energy as does normal ischemic myocardium
[38,41]. The activity of the nicotinamide adenine dinucleotide
diphosphate (NADPH)-dependent enzyme aldose reductase is
elevated in diabetes and following I/R injury, its activity is
increased further which serves to reduce myocardial glycolysis,
glucose oxidation and increases the formation of AGEs [42,43].
Furthermore, chronically elevated glucose levels have shown to
lead to ventricular hypertrophy and process which decreases the
overall vascular density within the myocardium. This phenomenon causes the diabetic to be extremely susceptible to endocardial
ischemia and I/R injury [38,44]. Recently, cytoprotective
cytokines such as interleukin (IL)-33 that are downregulated in
diabetic models, have also shown to have some role in increasing
the vulnerability of the myocardium to ischemic insult. Rui et al
recently showed that activation of protein kinase C-b in diabetes
contributes to IL-33 attenuation and increased I/R susceptibility
[44].
Therefore based on this background information, we propose
that PDE-5 inhibitors would be ideal candidates to treat insulin
resistance, and inflammation while protecting the diabetic heart
against I/R injury and MI-induced heart failure. Among the
currently available PDE-5 inhibitors, TAD has the advantage
because it is long acting whereas the durations of action of
sildenafil and vardenafil are generally 4 to 8 h [45]. Moreover,
TAD is a highly selective inhibitor of PDE with .10,000-fold
selectivity for PDE-5 over PDE-1 to PDE-4 and approximately
700-fold selectivity for PDE-5 over PDE-6 [45]. TAD is also the
only PDE-5 inhibitor whose activity is unaffected by food and has
a relatively short time to onset of action (16–17 min). Accordingly,
we investigated whether chronic TAD treatment will attenuate
inflammation and improve metabolic parameters such as body
weight and fasting blood glucose and triglyceride levels while
reducing infarct size through ameliorating cellular death pathways
such as apoptosis and necrosis. We used the db/db diabetic mouse
which has a point mutation of the leptin receptor that produces a
chronic diabetic state and mimics aspects of human type 2
diabetes, including obesity, fasting hyperglycemia and insulin
resistance [46,47]. Insulin resistance is the earliest phenotypic
change in these mice, evident by 10–12 days of age, with glucose
intolerance to oral glucose challenge and reduced hypoglycemic
response to insulin injection by 8–12 weeks of age [48].

Materials and Methods
Animals
Twenty leptin receptor null, homozygous db/db mice (strain
B6.Cg-m +/+Leprdb/J) were purchased at a mean age of 12 weeks
and treated for 4 weeks. All animals were purchased from The
Jackson Laboratory (Bar Harbor, ME), and had the same genetic
background [49]. The animal experiment protocols were approved by the Institutional Animal Care and Use Committee of
Virginia Commonwealth University. All animal experiments were
conducted under the guidance on humane use and care of
laboratory animals for biomedical research published by the
National Institutes of Health (No. 85-23, Revised 1996).

Protocol for Animal Experiments
Twelve db/db mice were randomized to receive daily intraperitoneal (i.p.) injections of TAD (1 mg/Kg in 10% dimethylsulf2
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oxide [DMSO]) or daily i.p. injections of an equivalent volume of
vehicle (10% DMSO in 0.9% NaCl) for 28 days as outlined in
Fig. 1. The TAD dose was chosen based on interspecies dose
extrapolation scaling to result in plasma concentrations equivalent
to those found in humans receiving an oral dose of 20 mg/day. All
mice had food (standard chow) and water provided ad libitum. Each
animal had specific metabolic parameters monitored during the
treatment period, including weekly fasting blood glucose levels and
body weight. Upon completion of treatment, mice were anesthetized with pentobarbital sodium (70 mg/Kg, i.p.) and via
thoracotomy, blood samples were taken by cardiac puncture for
evaluating plasma inflammatory cytokines and chemokines.

(K–H) solution containing (in mM) 118 NaCl, 24 NaHCO3, 2.5
CaCl2, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 11 glucose, and 0.5
EDTA. The perfusion solution was continuously gassed with 95%
O2+5% CO2 (pH ,7.4) and warmed by a heating/cooling bath.
The heart temperature was continuously monitored and maintained at 37uC throughout the experiment. Ventricular function
was measured by a force-displacement transducer (model FT03,
Grass) attached to the apex with a no. 5 surgical thread and a rigid
metal hook. The resting tension of the isolated heart was adjusted
to approximately 0.30 g. Ventricular developed force was
continuously recorded with a PowerLab 8SP computerized data
acquisition system connected to the force transducer. Coronary
flow rate was calculated by timed collection of the perfusate. The
hearts were not paced.

Langendorff Isolated Perfused Heart Preparation
The methods for the isolated, perfused mouse heart preparation
have been previously described in detail [24]. In brief, mice
treated with TAD or DMSO control group were anesthetized with
pentobarbital sodium (100 mg/Kg) and heparin (33 units i.p.) and
the hearts were quickly removed from the thorax and placed in a
small dish containing ice-cold perfusate and heparin. The aortic
opening was rapidly cannulated and tied on a 20-gauge blunt
needle that was connected to a Langendorff perfusion system.
After cannulation, the heart was retrogradely perfused at a
constant pressure of 55 mm Hg with modified Krebs–Henseleit

Isolation of Adult Mouse Ventricular Cardiomyocytes
Four weeks after treatment with TAD or DMSO, 8 adult male
leptin receptor null, homozygous db/db mice (strain B6.Cg-m +/
+Leprdb/J) [49] were used to isolate ventricular cardiomyocytes.
The ventricular cardiomyocytes were isolated using an enzymatic
technique modified from the previously reported method [49–51].
In brief, the animal was anesthetized with pentobarbital sodium
(100 mg/Kg, i.p.) and the heart was quickly removed. Within
3 min, the aortic opening was cannulated onto a Langendorff

Figure 1. Experimental Protocol. Mice were treated with TAD (1 mg/Kg) or an equivalent volume of DMSO for 28 days. The hearts were, isolated
and subjected to 20 min stabilization, followed by 30 min of no-flow global ischemiaand 60 min of reperfusion in a Langendorff model. At the time
of sacrifice, serum samples were also collected for inflammatory cytokine and chemokine analysis. A second subset of db/db mice were treated and
hearts were collected. The ventricular cardiomyocytes were isolated and subjected to 40 min of simulated ischemia (SI) followed by either 1 h or 18 h
of reoxygenation (RO) for evaluation of necrosis and apoptosis as described under Methods.
doi:10.1371/journal.pone.0045243.g001
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24 NaHCO3, 1.0 NaH2PO4, 2.5 CaCl2–2H2O, 1.2 MgCl2, 20
sodium lactate, 16 KCl, 10 2-deoxyglucose (pH adjusted to 6.2). In
addition, the cells were incubated under hypoxic conditions at
37uC during the entire SI period by adjusting the tri-gas incubator
to 1–2% O2 and 5% CO2. Reoxygenation (RO) was accomplished
by replacing the ischemic buffer with normal medium under
normoxic conditions. Assessment of cell necrosis was performed
after 1 h after RO as seen in Fig. 1.

perfusion system and the heart was retrogradely perfused (37uC) at
a constant pressure of 55 mmHg for approximately 5 min with a
Ca2+-free bicarbonate-based buffer containing (in mM): 120 NaCl,
5.4 KCl, 1.2 MgSO4, 1.2 NaH2PO4, 5.6 glucose, 20 NaHCO3, 10
2, 3-butanedione monoxime, and 5 taurine, which was continuously bubbled with 95% O2+5% CO2. The enzymatic digestion
was commenced by adding collagenase type II (Worthington,
0.5 mg/mL each) and protease type XIV (0.02 mg/mL) to the
perfusion buffer and continued for ,15 min. 50 mM Ca2+ was
then added in to the enzyme solution for perfusing the heart for
another 10–15 min. The digested ventricular tissue was cut into
chunks and gently aspirated with a transfer pipette for facilitating
the cell dissociation. The cell pellet was resuspended for a 3-step
Ca2+ restoration procedure (i.e., 125, 250, 500 mM Ca2+). The
freshly isolated cardiomyocytes were then suspended in minimal
essential medium (Sigma catalogue# 6 M1018, pH 7.35–7.45)
containing 1.2 mM Ca2+, 12 mM NaHCO3, 2.5% fetal bovine
serum, and 1% penicillin–streptomycin. The cells were then plated
onto the 35 mm cell culture dishes, which were pre-coated with
20 mg/ml mouse laminin in PBS +1% penicillin–streptomycin for
1 h. The cardiomyocytes were cultured in the presence of 5%
CO2 for 1 h in a humidified incubator at 37uC, which allowed
cardiomyocytes to attach to the dish surface prior to the
experimental protocol.

Evaluation of Cell Viability and Apoptosis
Cell viability was assessed by trypan blue exclusion assay and by
lactate dehydrogenase (LDH) release in the cell medium. At the
end of protocol, 20 mL of 0.4% trypan blue (Sigma-Aldrich) was
added into the culture dish. After approximately 5 min of
equilibration, the cells were counted under microscope. For
LDH measurements, the cellular medium was collected, and the
enzyme activity was monitored spectrophotometrically using an
assay kit (Sigma-Aldrich).
Cardiomyocyte apoptosis was evaluated by using terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) with an ApopTag in situ apoptosis detection kit
(Millipore Bioscience Research Reagents, Temecula, CA) according to the manufacturer’s instructions. The quantification of
apoptosis was determined by counting the TUNEL-positive
myocyte nuclei from five random fields per section and was
expressed as percentage of total myocyte nuclei as previously
reported [26].

Glucose Measurements
Blood glucose concentrations were obtained using a handheld
glucometer, (Lifescan, Milpitas, CA) using 5 ml of blood obtained
from tail vein from 12 h fasted mice and applied directly to glucose
test strips to measure fasting glucose levels on a weekly basis.

Protein Kinase G Activity
Protein kinase G activity was examined using a commercially
available PKG activity kit (Cyclex; Nagano, Japan) in ventricular
cardiomyocytes (n = 4/group). Activity was measured according to
the manufacturer’s instructions. Spectrophotometric absorbance
was measured at 450 nm. Results were normalized as per
milligram of protein.

Measurement of Plasma Inflammatory Cytokines and
Chemokines
At the time of sacrifice, blood was collected by cardiac puncture
into 2 separate ethylenediaminetetraacetic acid (EDTA) tubes,
stored immediately on ice and centrifuged at 4uC, 3,000 g for 10
minutes. The serum and plasma were separated and stored at
280uC until analyzed. Plasma concentrations of representative
cytokines: IL-1a, IL-1b, IL-2, IL-3, IL-5, IL-6, IL-8, IL-10, IL-12,
IL-13, IL-17, TNF-a, interferon (IFN)-c and chemokines:
RANTES (Regulated upon Activation, Normal T-cell Expressed,
and Secreted) also known as CCL (C-C chemokine ligand)-5,
MIP-1a and -1b (macrophage inflammatory protein) which are
also known as CCL-3 and CCL-4 was quantified using the BioPlex Pro magnetic cytokine assay (Bio-Rad, Hercules, CA). Plasma
samples were assayed for triglycerides using commercially
available colorimetric assay kits (Cayman Chemicals, Ann Arbor,
MI).

Statistics
Continuous variables are expressed as mean 6 standard error.
Two-way analysis of variance (ANOVA) was used to compare preand post-intervention values between the 2 groups. Student’s T
test was used for comparison of unpaired data between 2 groups
and the one-way ANOVA to compare unpaired data between 3 or
more groups. Discrete variables are expressed as percentage and
the Chi-square or Fisher’s exact tests are used accordingly.
Unadjusted two-tailed P values ,0.05 are considered statistically
significant.

Results

Infarct Size Assessment

Effect of TAD on Fasting Plasma Glucose and Triglyceride
Levels and Body Weight

At the end of reperfusion, the heart was immediately removed
from the Langendorff apparatus, weighed and frozen at 220uC.
The frozen heart was cut into six to seven transverse slices, stained
by 10% tetrazolium chloride for 30 min at room temperature
(,22uC), and subsequently fixed with 10% formalin for 2 to 4 h.
The infarct area was determined by computer morphometry by
using Bioquant Imaging Software. The infarct size was presented
as percentage of risk area.

Fasting plasma glucose levels and body weight were evaluated
weekly whereas plasma triglyceride levels were measured upon
completion of therapy. The db/db mice treated with TAD showed
a significant decrease in fasting plasma glucose levels
(292631.8 mg/dL vs. 511619.3 mg/dL) compared to controls
after the treatment period, [n = 6/group; Fig. 2A]. Similarly, there
was a dramatic decline in fasting triglycerides in TAD treated db/
db mice (43.3621 vs. 129.7629 mg/dL, p,0.05, n = 6; Fig. 2B).
However, body weight remained unchanged between control db/
db and TAD treated db/db mice (41.461.2 g vs. 45.861.7 g)
[n = 6/group; Fig. 2C].

Cardiomyocytes Experimental Protocol
The cultured cardiomyocytes were subjected to simulated
ischemia (SI) for 40 min by replacing the cell medium with an
‘‘ischemia buffer’’ which contained (in mM): 118 NaCl,
PLOS ONE | www.plosone.org
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Figure 2. Effect of TAD on fasting blood glucose and body weight. The db/db mice were treated with TAD or DMSO as described in Figure 1
A: Fasting blood glucose levels. B: Triglycerides. There was a significant decline in plasma triglyceride levels in the TAD group compared to control. C:
Body weight. TAD treatment had significant effect in reducing blood glucose levels.
doi:10.1371/journal.pone.0045243.g002

Treatment with TAD resulted in decrease of ,64% of trypan
blue-positive cardiomyocytes (i.e., 21.361.5%; p,0.001 vs.
control, n = 4; Fig. 5A). Similarly, TAD treated cardiomyocytes
demonstrated attenuated LDH release in the cell medium
compared to control after SI/RO (p,0.01, n = 4; Fig. 5B). After
18h of RO, apoptosis was also inhibited as indicated by reduced
number of TUNEL-positive cells in TAD treated cardiomyocytes
(23.461.9% vs. 8.861% in the TAD treated group, (p,0.001,
n = 4; Fig. 5C).

Effect of TAD on Infarct Size
Following I/R, infarct size was reduced after chronic treatment
with TAD for 28 days as compared to vehicle (DMSO)-treated db/
db mice (23.261.5% vs. 47.863.7%, p,0.01, n = 6/group; Fig. 3).
There was no significant difference in the pre-ischemia basal
functional parameters (i.e. developed force, rate-force product,
and resting tension) between the two treatment groups (n = 6/
group). The post-ischemic rate-force product (expressed as % of
pre-ischemic baseline compared to the control group) was not
changed (72.262.9% vs. 63.863.8%, p = 0.10, n = 6/group;
Fig. 4A). However, the coronary flow rate improved in the TAD
treated db/db mice (147.463.2% of the pre-ischemic baseline vs.
98.361.2% in the DMSO treated mice, p = 0.005, n = 6/group;
Fig. 4B.) Baseline and post-ischemic coronary flow rates ranged
from 1.8 to 2.1 mL/min and 1.7 to 1.9 mL/min in the TAD
group, respectively and 1.7 to 2.0 mL/min and 1.5 to 1.6 mL/
min in the control group, respectively.

Effect of TAD on Protein Kinase G Activity
TAD treated cardiomyocytes had a 44.362.5% increase in
PKG activity compared to C57BL/6 non-treated controls whereas
the DMSO treated group had a 16.761.8% decrease compared to
the non-diabetic control, p,0.001, n = 4, Fig. 5D.

Plasma Inflammatory Cytokine and Chemokine Levels
Nearly all pro-inflammatory cytokines were decreased when
measured after 28 days of treatment with TAD in the db/db mice
when compared to the DMSO-treated controls [Fig. 6A].
Specifically, the anti-inflammatory cytokine IL-10 was increased
in the TAD treated mice as compared to DMSO, (p,0.001,
n = 6/group; Fig. 6B). TNF-a and IL-1b were significantly
reduced compared to control (257616.51 vs. 402.3617.26 and
150.8612.55 vs. 264631.85 pg/mL, respectively; P,0.001),

Effect of TAD on Cardiomyocyte Necrosis and Apoptosis
We further evaluated the effect of TAD treatment in protection
of primary cardiomyocytes isolated from db/db mice against SI/
RO injury. Our method of cell preparations yielded at least 85–
90% of the cardiomyocytes with rod shape morphology. After
40 min of SI and 1 h of RO, the percent of trypan blue-positive
(necrotic) cardiomyocytes was 59.861.5 in the control group.
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which is shown to suppress inflammation. Furthermore, the
number of T cells that secrete IL-10 dramatically decrease in
proportion to increasing obesity [52].
Macrophage inflammatory protein-1b (MIP-1b), monocyte
chemotactic protein-1 (MCP-1) and Regulation upon Activation,
Normal T-cell Expressed and Secreted (RANTES) are three
chemokines with the C-C ligand motif and play a significant role
in the activation and proliferation of the inflammatory cascade,
especially in adipose tissue and the endothelium [53]. Not
surprisingly, TNF-a can activate MCP-1 and MIP-1b which
further recruits macrophages to the adipose tissue hence potentiating the inflammation [54]. This invariably leads to the chronic
low-level state of inflammation found in obesity. We found that
along with reduced levels of TNF-a, the chemokines MIP-1b,
MCP-1 and RANTES were all significantly reduced.
The role of IL-6 in insulin resistance has been controversial and
sometimes paradoxical. Concentrations of IL-6 are increased in
obesity and have been shown to predict the incidence of type 2
diabetes in individuals [55]. However, as hepatic and adipose
production of IL-6 promote insulin resistance, IL-6 produced by
skeletal muscle especially during intense exercise is beneficial [56].
Further adding to this controversy, mice with the genetic deletion
of IL-6 have significant hepatic inflammation and develop insulin
resistance [57]. Despite a slight reduction in circulating levels of
IL-6 in the treatment group, the difference was not statistically
significant.
Our results also show that TAD, similar to other PDE-5
inhibitors in non-diabetic models, significantly reduces infarct size
following I/R in the diabetic heart and attenuates necrosis and
apoptosis following SI/RO in isolated ventricular cardiomyocytes
(Fig. 5A–C). Cardiac function did not improve significantly in the
treatment group during isolated I/R, albeit there was a trend
towards improved cardiac performance in addition to improved
coronary flow rates. Using proteomic analysis, our laboratory
recently demonstrated that chronic TAD treatment (28 day
treatment) modulates cardiac proteins, specifically those associated
with cytoskeletal rearrangement such as myosin light chain-2,
myosin light chain-4, myosin heavy chain-a, and myosin binding
protein-C [58]. These data suggest that TAD therapy may

Figure 3. Effect of TAD on myocardial infarct size. Treatment
with TAD significantly reduced infarct size when compared to the
DMSO-treated control group, p = 0.011; n = 6/group.
doi:10.1371/journal.pone.0045243.g003

while IL-6 was not changed i.e, 27.861.1 pg/mL vs.
32.361.3 pg/mL, p = 0.08, n = 6/group; Fig. 6C. The chemokines RANTES (CCL-5), MIP-1b (CCL-4), and MCP-1 (CCL-2)
were also reduced significantly [n = 6/group; Fig. 6A]. Chemokines MIP-1a (CCL-3) and Eotaxin, however, were not reduced
significantly with TAD treatment.

Discussion
In the present study, we showed for the first time that circulating
levels of two key pro-inflammatory cytokines, TNF-a and IL-1b
were significantly reduced after chronic TAD treatment. There was
a trend towards a reduction in IL-6, whereas the anti-inflammatory
cytokine IL-10 was significantly higher in TAD treated db/db mice
compared to control. With an overall decreased inflammatory
profile, improved fasting plasma glucose and triglyceride levels and
a trend towards decreased body weight, our results correlate with
previously published data and known physiological pathways, that
IL-10 levels are inversely proportional to adiposity [52]. The
adipose tissue of lean mice secretes an unusually high level of IL-10

Figure 4. Cardiac function and coronary flow. A: Cardiac function presented as the double product of the heart rate and ventricular developed
force (percentage of the pre-ischemic baseline) is shown. B: Coronary flow. The post-ischemic cardiac function remained unchanged whereas
coronary flow was significantly improved in the TAD group (as a percentage of pre-ischemia baseline, p = 0.005).
doi:10.1371/journal.pone.0045243.g004
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Figure 5. Effect of TAD in protection of ventricular cardiomyocytes against necrosis and apoptosis following simulated ischemia/
reoxygenation. Necrosis was determined by trypan-positive (A) and LDH release in the medium (B); apoptosis was determined by TUNEL staining
(C). TAD treated group had significantly lower trypan-blue positive cardiomyocytes and LDH release in the medium as compared with control (n = 4/
group). Similarly, TAD treatment significantly reduced apoptotic cells when compared to DMSO, p,0.001, n = 4/group. (D): PKG activity. PKG activity
was significantly higher in the TAD group, p,0.001, n = 4/group.
doi:10.1371/journal.pone.0045243.g005

downregulate cytoskeletal contractile proteins associated with
cardiac remodeling and heart failure. We also found that in vivo
cardiac dysfunction was only seen after 24 weeks of age compared
to the non-diabetic controls. This may explain why no significant
improvement in cardiac function was noted after only 28 days of
TAD treatment. In these experiments, the average age of db/db
mice was approximately 16 weeks, which was too early to observe
significant upregulation in cytoskeletal contractile proteins and
consequent functional impairment of myocardial contraction.
It has been reported that leptin itself is protective after I/R
injury through the induction of signal transducer and activator of
transcription-3, which leads to downstream activation of cardioprotective genes [59,60]. The leptin deficient mouse has impaired
cardiac function after I/R injury in addition to higher cardiomyocyte death by apoptosis, ventricular hypertrophy and heart
failure [60]. Apparently the lack of synthesis of cardioprotective
genes in leptin knock-out mice may cause larger infarct size as
compared to wild-type mice.
In the present study, although body weight was not significantly
reduced, fasting plasma glucose levels was observed after 3 weeks
of treatment. PKG activity was significantly increased in the TAD
treated cardiomyocytes as compared to DMSO controls
(Figure 5D). We propose that restoration of NO-sGC-PKG
PLOS ONE | www.plosone.org

signalling following chronic treatment with TAD could affect
insulin resistance and improve fasting blood glucose levels. Given
the improved NO bioavailability and vasodilatation with PDE-5
inhibitors [61], there is increased blood flow for muscle glucose
utilization and additionally, the decreased TNF-a in the circulation may potentially attenuate the amount of IRS-1 receptor
phosphorylation and improve insulin signalling. It has also been
postulated that chronic PDE-5 inhibitor treatment may increase
fatty acid oxidation and may also be a potential mechanism for
preventing insulin resistance. In a mouse model of diet-induced
obesity and insulin resistance, chronic sildenafil treatment was able
to improve insulin action and decrease body mass [2]. Moreover,
it has been shown that prolonged treatment with TAD in C2C12
myoblasts improved oxidative capacity as demonstrated by
increase in fatty acid metabolism, including the activities of citrate
synthase and 3-OH acylCoA dehydrogenase [62]. One possible
explanation is that PKG has been shown to affect insulin signaling
and mitochondrial biogenesis in brown adipose tissue by inhibiting
the activity of RhoA and Rho-associated kinase (ROCK), thereby
relieving the inhibitory effects of ROCK on IRS-1 [63]. This
allows the activation of the phosphotidyl-inositol-3-kinase (PI3K)Akt signaling cascade downstream of the insulin receptor. In
addition, Haas et al showed that PKG mediated the ability of NO
7
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Figure 6. Effect of TAD on plasma inflammatory cytokines and chemokines. TAD treatment caused reductions in the cytokines IL-1b, TNF-a,
IFN-c, and chemokines MIP-1b, MCP-1, and RANTES (p,0.01, compared to DMSO; n = 6/group) as shown in ‘A’’. The levels of IL-10 was higher in TAD
treated mice than control, (p,0.001; n = 6/group) as shown in ‘B’. No significant changes in the IL-6 levels were observed between the two groups as
shown in ‘C’.
doi:10.1371/journal.pone.0045243.g006

and cGMP to induce mitochondrial biogenesis and increase the
expression of uncoupling protein-1 (UCP-1), a protein necessary in
energy expenditure through thermogenesis [63]. Similarly, NO
and eNOS have been shown to directly correlate with mitochondrial biogenesis as the abundance of peroxisome proliferator
activated receptor-gamma (PPAR-c) [64,65].
Oxidative stress mediated by hyperglycemia-induced generation
of ROS contributes significantly to the development and
progression of diabetes and related vascular damage [66]. Diabetes
is usually accompanied by increased production of free radicals
and impaired antioxidant mechanisms. Moreover, ROS are
involved in insulin resistance via its regulatory effects on
mitochondrial function [67,68]. The diabetic vessels from animal
models and endothelial derived cells in cell culture models under
hyperglycemic conditions exhibit high levels of ROS associated
with decreased levels of endothelial NO [69,70]. The chronic
treatment with TAD in diabetic mice was shown to improve redox
signaling by enhancing the antioxidant enzyme glutathione Stransferase Kappa-1 (GSKT-1) and downregulate redox regulato-

ry chaperones, heat shock protein 8 and 75 kDa glucose
regulatory protein [58]. Moreover, TAD treated diabetic mice
had significantly lower levels of GSSG/GSH suggesting reduction
of oxidative stress [58].
In summary, we have provided evidence that TAD therapy
ameliorates circulating inflammatory cytokines and chemokines in
a diabetic model while improving fasting glucose levels and
reducing infarct size following I/R injury in the heart. These
results suggest that daily use of PDE-5 inhibitors may be a
promising therapy for cardioprotection as well as reduction of proinflammatory cytokines in diabetic patients.
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